Search
forLearn
5 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn trimethicone
learn Verteporfin
chemical that might completely regrow follicles from hair transplant extractions
learn TeraCeutic™
Research
5 / 342 resultsresearch Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy
Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.
research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.
Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
research Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
research Management of Chemotherapy-Induced Alopecia With Scalp Cooling
Scalp cooling is an effective and safe way to prevent hair loss from chemotherapy, with manageable side effects and low risk of scalp cancer.
research Topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a phase I safety study.
Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
Community Join
5 / 1000+ resultscommunity GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community Any other treatments to still be hopeful for?
The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.